EV Targeting MCF-7 Breast Cancer Cell Lines Inhibit Both mTOR and HIF-1A: Molecular Docking Study
Keywords:Breast Cancer, mTOR, HIF-1A, Everolimus, Docking
Background and Objective: The mortality dramatically increase in breast cancer are caused by inadequate
of the benefits of different types of therapies. mTOR is an atypical serine/threonine protein kinase that
belongs to the phosphoinositide 3-kinase (PI3K)-related kinase family. The aim of this study to investigation
of ability of EV to inhibiting both mTOR and HIF-1A through MCF-7 BC cell lines targeting and docking
study by specific computational program.
Method: In vitro cytotoxicity study of different doses of EV were quantitatively measured by employing on
MCF-7 cell lines. Docking study was done by computing 3D programs (in silico), the information in protein
data bank (PDB) Zinc15docking and phyre2 protein homology tools.
Results: There was another suggestion for inhibition of HIF-1A protein (PDB reference code 4AJY) by
incubation of MCF-7 cells with 5 mg/day of EV that is may be binding of EV as analogue in other sites
differs from active site and may be stimulate the hydroxylation and acetylation of the protein and enhanced
normal degradation pathway.
Conclusion: This study suggesting the mechanism of inhibition of HIF-1A by EV in addition to inhibition
of mTOR pathway.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.